5 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Microbiome Influence on Energy balance and Brain Development-Function Put into Action to Tackle Diet-related Diseases and Behavior (MyNewGut)
Date du début: 1 déc. 2013, Date de fin: 30 nov. 2018,
Emerging evidence indicates that the gut microbiome contributes to our ability to extract energy from the diet and influences development and function of the immune, endocrine and nervous systems, which regulate energy balance and behaviour. This has led to hypothesize that developing microbiome-based dietary interventions can be cost-effective measures to prevent diet-related and behavioural diso ...
Voir le projet
30
Participants partenaires
TERMINÉ
European Medical Information Framework (EMIF)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,
In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information gaps which prevent their full exploitation. EMIF aim ...
Voir le projet
64
Participants partenaires
TERMINÉ
Determinants of eating behaviour in European children, adolescents and their parents (I.Family)
Date du début: 1 mars 2012, Date de fin: 28 févr. 2017,
Nutrition-related diseases caused a loss of over 56 million years of healthy life of European citizens in 2000. I.Family will make a significant contribution to reduce this burden by studying the interplay and impact of the main drivers of dietary behaviour and food choice. It will take advantage of the unique opportunity to follow-up the large IDEFICS children’s cohort to not only provide added v ...
Voir le projet
17
Participants partenaires
TERMINÉ
Safety Evaluation of Adverse Reactions in Diabetes (SAFEGUARD)
Date du début: 1 oct. 2011, Date de fin: 30 sept. 2015,
"In 2010 a widely marketed drug for the treatment of type 2 diabetes (T2DM) (rosiglitazone) was taken from the market as it was associated with an increased risk of myocardial infarction, a T2DM complication it was actually supposed to prevent. This example shows several things. First, the approval requirements do not guarantee a longer term positive benefit risk profile. Second, large scale postm ...
Voir le projet
19
Participants partenaires
TERMINÉ
Arrhythmogenic potential of drugs (ARITMO)
Date du début: 1 janv. 2010, Date de fin: 30 juin 2013,
The ability of some compounds to prolong the QT interval of the electrocardiogram and to precipitate Torsade de Pointes (TdP, a potentially fatal arrhythmia) has caused several regulatory interventions, including drug withdrawals. Specific guidelines have been implemented to detect QT liability of new compounds as early as possible. However there is growing evidence that an increase in the QT inte ...
Voir le projet